NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.

TerminatedN/A

Sponsor: University of North Carolina, Chapel Hill

Conditions: RELAPSING REMITTING MULTIPLE SCLEROSIS

Countries: United States

The purpose of this research is to characterize the effect of teriflunomide on the activation of B-cells, as well as its capacity to modify B-cell cytokine secretion. The in-vitro identified effects of teriflunomide on the expression of B-cell activation markers, costimulatory and antigen presenting molecules, as well as on cytokine secretion, will then be confirmed in a cohort of Relapsing Remitting Multiple Sclerosis (RRMS) patients treated with this medication.

Eligibility overview

Sex: ALL

Age: 18 Years to 55 Years

Healthy volunteers: Yes

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* confirmed diagnosis of RRMS according to McDonald's diagnostic criteria,
* age 18-55,
* an extended disability status score (EDSS) of 1.5-5.5.

Exclusion Criteria:

\- Previous treatment with DMT.

Locations (1)

Chapel Hill, North Carolina, United States